Hematopoietic cell destruction by immune mechanisms in acquired aplastic anemia

Seminars in Hematology

Volumn 37, Issue 1, 2000, Pages 3-14

  Young, Neal S ^a,b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

APLASTIC ANEMIA; AUTOIMMUNE DISEASE; BONE MARROW DEPRESSION; CELL DESTRUCTION; HEMATOPOIESIS; HEMATOPOIETIC CELL; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0033950194     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0037-1963(00)90026-X     Document Type: Article

References (92)

1. Abkowitz JL, Linenberger ML, et al: Evidence for the maintenance of hematopoiesis in a large animal by the sequential activation of stem-cell clones. Proc Natl Acad Sci USA 87:9062-9066, 1990
2. Alter MJ, Gallagher M, Morris TT, et al: Acute non-A-E hepatitis in the United States and the role of hepatitis G virus infection. N Engl J Med 336:741-746, 1997
3. Anderson KC, Weinstein HJ: Transfusion-associated graft versus-host disease. N Engl J Med 323:315-321, 1990
4. Aoki I, Higashi K, Homori M, et al: Rssponsiveness of bone marrow erythropoietic stem cells (CFU-E and BFU-E) to recombinant human erythropoietin (rh-Ep) in vitro in aplastic anemia and myelodysplastic syndrome. Am J Hematol 35:6-12, 1990
5. Araten D, Nafa K, Pakdeesuwan K, et al: Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc Natl Acad Sci USA 96:5209-5214, 1999
6. Baciagalupo A, Piaggio G, Figari O, et al: Response of CFU-GM to increasing doses of rhGM-CSF in patients with aplastic anemia. Exp Hematol 19:829-832, 1991
7. Bacigalupo A, Podesta M, Frassoni F, et al: Generation of CFU-C suppressor T cells in vitro V. A multistep process. Br J Haematol 52:421-427, 1982
8. Bacigalupo A: Aetiology of severe aplastic anaemia and outcome after allogeneic bone marrow transplantation or immunosuppression. Eur J Haematol 57:16-19, 1996 (suppl 60)
9. Ball SE, Gibson FM, Rizzo S, et al: Progressive telomere shortening in aplastic anemia. Blood 91:3582-3592, 1998
10. + T cells in persistent infection with lymphocytic choriomeningitis virus. J Exp Med 187:1903-1920, 1998
11. Birk OS, Gur SL, Elias D, et al: The 60-kDa heat shock protein modulates allograft rejection. Proc Natl Acad Sci USA 96:5159-5163, 1999
12. Brown KE, Tisdale J, Dunbar CE, et al: Hepatitis-associated aplastic anemia. N Engl J Med 336:1059-1064, 1997
13. Cahill DP, Lengauer C, Yu J, et al: Mutations of mitotic checkpoint genes in human cancers. Nature 392:300-303, 1998
14. Chapuis B, Von Fliedner VE, Jeannet M, et al: Increased frequency of DR2 in patients with aplastic anaemia and increased DR sharing in their parents. Br J Haematol 63:51-57, 1986
15. Corwin AL, Dai TC, Duc DD, et al: Acute viral hepatitis in Hanoi, Viet Nam. Trans R Soc Trop Med Hyg 90:647-648, 1996
16. Dalal M, Kim S, Voskuhl RR: Testosterone dierapy ameliorates experimental autoimmune encephalomyelitis and induces a T helper 2 bias in the autoantigen-specific T lymphocyte response. J Immunol 159:3-6, 1997
17. Devetten MP, Young NS: Hematopoietic growth factors in the pathophysiology and treatment of aplastic anemia, in Hoelzer D, Ganser A (eds): Cytokines in the Treatment of Hematopoietic Failure. New York, NY, Marcel Dekker, 1998, pp 155-169
18. Dunn DE, Tannawattanacharoen P, Boccuni P, et al: Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med 131:401-408, 1999
19. Dunn DE, Yu J, Nagarajan S, et al: A knock-out model of paroxysmal nocturnal hemoglobinuria: PIG-A- hematopoiesis is reconstituted following intercellular transfer of GPI-anchored proteins. Proc Natl Acad Sci USA 93:7938-7943, 1996
20. Ehl S, Hombach J, Aichele P, et al: Bystander activation of cytotoxic T cells: Studies on the mechanism and evaluation of in vivo significance in a transgenic mouse model. J Exp Med 185:1241-1251, 1997
21. Fleischhauer K, Kernan NA, O'Reilly RJ, et al: Bone marrow-allograft rejection by T lymphocytes recognizing a single amino acid difference in HLA-B44. N Engl J Med 323:1818-1822, 1990
22. Gale RE, Wainscoat JS: Clonal analysis using X-linked DNA polymorphisms. Br J Haematol 85:2-8, 1993
23. Gascon P, Zoumbos N, Young NS: An analysis of natural killer cells in aplastic anemia. Blood 67:1349-1355, 1986
24. Gerson WT, Fine DG, Spielberg SP, et al: Anticonvulsant-induced aplastic anemia: Increased susceptibility to toxic drug metabolites in vitro. Blood 61:889-893, 1983
25. Hertenstein B, Wagner B, Bunjes D, et al: Emergence of CD52-, phosphatidylinositolglycan-anchor-deficient T lymphocytes after in vivo application of Campath-1H for refractory B-cell non-Hodgkin lymphoma. Blood 86:1487-1492, 1995
26. Ito K, Yoshida H, Yanagibashi K, et al: Change of HLA phenotype in postoperative erythroderma. Lancet 1:413-414, 1988
27. Jonasova A, Neuwirtova R, Cermak J, et al: Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 200:304-309, 1998
28. Kagan WA, Ascensao JA, Pahwa RN, et al: Aplastic anemia: Presence in human bone marrow of cells that suppress myelopoiesis. Proc Natl Acad Sci USA 73:2890-2894, 1976
29. Kawagoe K, Kitamura D, Okabe M, et al: Glycosylphosphatidylinositol-anchor-deficient mice: Implications for clonal dominance of mutant cells in paroxysmal nocturnal hemoglobinuria. Blood 87:3600-3606, 1996
30. Kearns WG, Liu J, Aridgides L, et al: Genomic instability in bone marrow failure syndromes: High frequency of aneuploidy by fluorescence in situ hybridization and identification of a spindle checkpoint gene mutation. Blood 1999 (suppl 1, abstr) (in press)
31. Kelton HG, Huang AT, Mold N, et al The use of in vitro technics to study drug-induced pancytopenia. N Engl J Med 301:621-624, 1979
32. Kim S-C, Min Y-H, Lee S, et al: Delayed activation-induced T lymphocytes death in aplastic anemia: Related with abnormal Fas system. Korean J Intern Med 13:41-46, 1998
33. Koijima S: Hematopoietic growth factors and marrow stroma in aplastic anemia. Int J Hematol 68:19-28, 1998
34. Kojima S, Matsuyama T, Kodera Y: Plasma levels and production of soluble stem cell factor by marrow stromal cells in patients with aplastic anaemia. Br J Haematol 99:440-446, 1997
35. Laver J, Castro-Malaspina H, Kernan NA, et al: In vitro interferon-gamma production by cultured T-cells in severe aplastic anaemia: Correlation with granulomonopoietic inhibition in patients who respond to anti-thymocyte globulin. Br J Haematol 69:545-550, 1988
36. Lehmann PV, Forsthuber T, Miller A, et al: Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 358:155-157, 1992
37. Li S, Champlin R, Fitchen JH, et al: Abnormalities of myeloid progenitor cells after "successful" bone marrow transplantation. J Clin Invest 75:234-241, 1985
38. Lieberman JA, Yunis J, Egea E, et al: HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatry 47:945-948, 1990
39. Locasciulli A, Broccia G, Corda G, et al: Risk of cytogenetic abnormalities in patients with severe aplastic anemia receiving immunosuppression with or without G-CSF. Bone Marrow Transplant 23:530, 1999 (suppl 1, abstr)
40. Lyman SD, Seaberg M, Hanna R, et al: Plasma/serum levels of flt3 ligand are low in normal individuals and highly elevated in patients with Fanconi anemia and acquired aplastic anemia. Blood 86:4091-4096, 1995
41. Maciejewski JP, Anderson S, Katevas P, et al: Phenotypic and functional analysis of bone marrow progenitor cell compartment in bone marrow failure. Br J Haematol 87:227-234, 1994
42. Maciejewski JP, Hibbs JR, Anderson S, et al: Bone marrow and peripheral blood lymphocyte phenotype in patients with bone marrow failure. Exp Hematol 22:1102-1110, 1994
43. Maciejewski JP, Selleri C, Sato T, et al: Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anemia. Br J Haematol 91:245-252, 1995
44. Maciejewski JP, Selleri C, Sato T, et al: A severe and consistent deficit in marrow and circulating primitive hematopoietic cells (long term culture-initiating cells) in acquired aplastic anemia. Blood 88:1983-1991, 1996
45. Maciejewski JP, Selleri C, Sato T, et al: Nitric oxide suppression of human hematopoiesis in vitro: Contribution to inhibitory action of interferon-α and tumor necrosis factor-α. J Clin Invest 96:1085-1092, 1995
46. Maciejewski JP, Sloand EM, Sato T, et al: Impaired hematopoiesis in paroxysmal nocturnal hemoglobinuria/aplastic anemia is not associated with a selective proliferative defect in the glycosylphosphatidylinositol-anchored protein-deficient clone. Blood 89:1173-1181, 1997
47. Manz CY, Dietrich PY, Schnuriger V, et al: T-cell receptor β chain variability in bone marrow and peripheral blood in severe acquired aplastic anemia. Blood Cells Mol Dis 23:110-122, 1997
48. - hematopoietic precursors in aplastic anemia after immunosuppressive treatment. Am J Hematol 52:264-274, 1996
49. Marsh JCW, Chang J, Testa NG, et al: In vitro assesssment of marrow 'stem cell' and stromal cell function in aplastic anaemia. Br J Haematol 78:258-267, 1991
50. Mathé G, Amiel JL, Schwarzenberg L, et al: Bone marrow graft in man after conditioning by antilymphocytic serum. Br Med J 2:131-136, 1970
51. Maulopoulos L, Dimopoulos M: Magnetic resonance imaging of the bone marrow in hematologic malignancies. Blood 90:2127-2147, 1997
52. McGuire W, Knight JC, Hill AV, et al: Severe malarial anemia and cerebral malaria are associated with different tumor necrosis factor promoter alleles. J Infect Dis 179:287-290, 1999
53. McManus PM, Weiss L: Busulfan-induced chronic bone marrow failure: changes in cortical bone, marrow stromal cells, and adherent cell colonies. Blood 64:1036-1041, 1984
54. Melenhorst JJ, van Krieken JHJM, Dreef E, et al: T cells selectively infiltrate bone marrow areas with residual haemopoiesis of patients with acquired aplastic anaemia. Br J Haematol 99:517-519, 1997
55. + T cells in a patient with aplastic anemia. J Clin Invest 87:1567-1574, 1991
56. Molldrem J, Caples M, Mavroudis D, et al: Antithymocyte globulin (ATG) abrogates cytopenias in patients with myelodysplastic syndrome. Br J Haematol 99:699-705, 1997
57. Molldrem JJ, Jiang YZ, Stetler-Stevenson M, et al: Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 102:1314-1322, 1998
58. Mori T, Nishimura T, Ikeda Y, et al: Involvement of Fas-mediated apoptosis in the hematopoietic progenitor cells of graft-versus-host reaction-associated myelosuppression. Blood 92:101-107, 1998
59. Myint AA, Malkovska V, Morgan S, et al: Antilymphocyte globulin therapy enhances impaired function of natural killer cells and lymphokine activated killer cells in aplastic anemia. Br J Haematol 75:578-584, 1990
60. Nakamoto Y, Guidotti LG, Kuhlen CV, et al: Immune pathogenesis of hepatocellular carcinoma. J Exp Med 188: 341-350, 1998
61. Nakao S, Takamatsu H, Chuhjo T, et al: Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia. Blood 84:4257-4261, 1994
62. Nakao S, Takamatsu H, Yachie A, et al: Establishment of a CD4+ T cell clone recognizing autologous hematopoietic progenitor cells from a patient with immune-mediated aplastic anemia. Exp Hematol 23:433-438, 1995
63. Nakao S, Takami A, Takamatsu H, et al: Isolation of a T-cell clone showing HLA-DRB1 0405-restricted cytotoxicity for hematopoietic cells in a patient with aplastic anemia. Blood 89:3691-3699, 1997
64. Nakao S, Yamaguchi M, Shiobara S: Interferon gamma gene expression in unstimulated bone marrow mononuclear cells predicts a response to cyclosporine therapy in aplastic anemia. Blood 79:2532-2535, 1992
65. Nguyen T, Brunson D, Crespi CL, et al: DNA damage and mutation in human cells exposed to nitric oxide in vitro. Proc Natl Acad Sci USA 89:3030-3034, 1992
66. Nimer SD, Ireland P, Meshkinpour A, et al: An increased HLA DR2 frequency is seen in aplastic anemia patients. Blood 84:923-927, 1994
67. Nisticò A, Young NS: Gamma-interferon gene expression in the bone marrow of patients with acquired aplastic anemia. Ann Intern Med 120:463-469, 1994
68. Notaro R, Cimmino A, Tabarini D, et al: In vivo telomere dynamics of human hematopoietic stem cells. Proc Natl Acad Sci USA 94:13782-13785, 1997
69. Novitzky N, Jacobs P: Immunosuppressive therapy in bone marrow aplasia: The stroma functions normally to support hematopoeisis. Exp Hematol 23:1472-1477, 1995
70. Philpott NJ, Scopes J, Marsh JCW, et al: Increased apoptosis in aplastic anemia bone marrow progenitor cells: Possible pathophysiologic significance. Exp Hematol 23:1642-1648, 1995
71. Platanias L, Gascon P, Bielory L, et al: Lymphocyte subsets and lymphokines following anti-thymocyte globulin therapy in patients with aplastic anaemia. Br J Haematol 66:433-443, 1987
72. 'Podesta M, Piaggio G, Frassoni F, et al: The assessment of the hematopoietic reservoir after immunosuppressive therapy or bone marrow transplantation in severe aplastic anemia. Blood 91:1959-1965, 1998
73. Raghavachar A, Janssen JWG, Schrezenmeier H, et al: Clonal hematopoiesis as defined by polymorphic-X-linked loci occurs infrequently in aplastic anemia. Blood 86:2938-2947, 1995
74. Sato T, Selleri C, Young NS, et al: Inhibition of interferon regulatory factor-1 expression results in predominance of cell growth stimulatory effects of interferon-gamma due to phosphorylation of Stat1 and Stat3. Blood 90:4749-4758, 1997
75. Schrezenmeier H, Jenal M, Herrmann F, et al: Quantitative analysis of cobblestone area-forming cells in bone marrow of patients with aplastic anemia by limiting dilution assay. Blood 88:4474-4480, 1996
76. Selleri C, Maciejewski JP, Sato T, et al: Interferon-gamma constitutively expressed in the stromal microenviroment of human marrow cultures mediates potent hematopoietic inhibition. Blood 87:4149-4157, 1996
77. Selleri C, Sato T, Anderson S, et al: Interferon-γ and tumor necrosis factor-α suppress both early and late stages of hematopoiesis and induce programmed cell death. J Cell Physiol 165:538-546, 1995
78. Shetty V, Mundle S, Alvi S, et al: Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk Res 20:891-900, 1996
79. Sloand E, Maciejewski JP, Kim S, et al: Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood (in press)
80. Stacey MW, Mcaninch T, Santi L, et al: Glutathione-S transferase (GSTT1 and GSTM1) null genotypes in patients with aplastic anemia and myelodysplastic syndromes. Blood 1999 (suppl 1, abstr) (in press)
81. Tamai H, Sudo T, Kimura A, et al: Association between the DRB1*08032 histocompatibilty antigen and methimazole-induced agranulocytosis in Japanese patients with Graves disease. Ann Intern Med 124:490-494, 1996
82. Tong J, Bacigalupo A, Piaggio G, et al: In vitro response of T cells from aplastic anemia patients to antilymphocyte globulin and phytohemagglutinin: Colony-stimulating activity and lymphokine production. Exp Hematol 19:312-316, 1991
83. White JR, Josten KM, Chopra R, et al: Absence of N-RAS point mutations in peripheral with aplastic anaemia and paroxysmal nocturnal haemoglobinurea. Br J Haematol 91:921-923, 1995
84. Wolk A, Simon-Stoos K, Nami I, et al: A mouse model of immune-mediated aplastic anemia. Blood 10:158a, 1998 (suppl 1, abstr)
85. Yoshida K, Miura I, Takahashi T, et al: Quantitative and qualitative analysis of stem cells of patients with aplastic anemia. Scand J Haematol 30:317-323, 1983
86. Young NS: The problem of clonality in aplastic anemia. Dr. Dameshek's riddle, restated. Blood 79:1385-1392, 1992
87. Young NS: Drugs and chemicals, in Young NS, Alter BP (eds): Aplastic Anemia, Acquired and Inherited. Philadelphia, PA, Saunders, 1994, p 100
88. Young NS: Agranulocytosis, in Young NS (ed): The Bone Marrow Failure Syndromes. Philadelphia, PA, Saunders (in press)
89. Young NS, Barrett AJ: The treatment of severe acquired aplastic anemia. Blood 85:3367-3377, 1995
90. Zeng W, Nakano S, Takamatsu H, et al: Characterization of T-cell repertoire of the bone marrow in immune-mediated aplastic anemia: Evidence for the involvement of antigen-driven T-cell response in cyclosporine-dependent aplastic anemia. Blood 93:3008-3016, 1999
91. Zoumbos N, Djeu J, Young N: Interferon is the suppressor of lymphocytes generated by stimulated lymphocytes in vitro. J Immunol 133:769-774, 1984
92. Zoumbos N, Gascon P, Djeu J, et al: Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo. Proc Natl Acad Sci USA 82:188-192, 1985